ArriVent BioPharma (NASDAQ:AVBP) Stock Price Expected to Rise, Citigroup Analyst Says

ArriVent BioPharma (NASDAQ:AVBP) had its price objective upped by analysts at Citigroup from $31.00 to $33.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Citigroup’s target price points to a potential upside of 40.85% from the stock’s previous close.

AVBP has been the topic of a number of other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of ArriVent BioPharma in a research note on Wednesday, January 21st. Zacks Research raised ArriVent BioPharma from a “strong sell” rating to a “hold” rating in a research note on Friday, December 5th. HC Wainwright lifted their price target on ArriVent BioPharma from $42.00 to $44.00 and gave the stock a “buy” rating in a report on Friday. Truist Financial assumed coverage on shares of ArriVent BioPharma in a research report on Tuesday, November 25th. They set a “buy” rating and a $43.00 price target on the stock. Finally, Cantor Fitzgerald initiated coverage on shares of ArriVent BioPharma in a research report on Monday, December 22nd. They set an “overweight” rating for the company. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $41.11.

ArriVent BioPharma Trading Down 7.2%

Shares of NASDAQ AVBP opened at $23.43 on Friday. The stock has a market cap of $967.19 million, a PE ratio of -5.31 and a beta of 0.99. ArriVent BioPharma has a 12-month low of $15.47 and a 12-month high of $27.22. The company has a 50-day moving average of $22.20 and a 200 day moving average of $20.93.

ArriVent BioPharma (NASDAQ:AVBP) last released its earnings results on Thursday, March 5th. The company reported ($0.78) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.09. On average, sell-side analysts forecast that ArriVent BioPharma will post -2.74 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Bessemer Group Inc. acquired a new position in ArriVent BioPharma in the third quarter valued at about $26,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of ArriVent BioPharma by 27.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,006 shares of the company’s stock valued at $40,000 after acquiring an additional 438 shares during the last quarter. Russell Investments Group Ltd. raised its stake in shares of ArriVent BioPharma by 9,747.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 2,068 shares of the company’s stock valued at $38,000 after acquiring an additional 2,047 shares during the period. BNP Paribas Financial Markets raised its stake in shares of ArriVent BioPharma by 31.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,571 shares of the company’s stock valued at $56,000 after acquiring an additional 609 shares during the period. Finally, Group One Trading LLC acquired a new position in shares of ArriVent BioPharma in the 4th quarter worth approximately $57,000. Institutional investors and hedge funds own 9.48% of the company’s stock.

More ArriVent BioPharma News

Here are the key news stories impacting ArriVent BioPharma this week:

• Positive Sentiment: Oppenheimer reaffirmed an “outperform” rating and raised its price target to $50 (from $44), a large upside vs. the current price. Oppenheimer boosts PT to $50
• Positive Sentiment: Citigroup raised its price target from $31 to $33 and kept a “buy” rating, signaling more analyst conviction. Citigroup raises PT to $33
• Positive Sentiment: HC Wainwright raised its target from $42 to $44 and maintained a “buy” rating—another analyst upgrade supporting upside. HC Wainwright raises PT to $44
• Positive Sentiment: Unusually large options activity: traders bought about 1,832 call contracts (≈321% above typical call volume), indicative of short-term bullish positioning.
• Positive Sentiment: Quarterly EPS beat: AVBP reported loss-per-share of ($0.78) vs. consensus ($0.87), a small beat that reduces near-term execution risk. Quarterly results press release
• Neutral Sentiment: Company released full-year 2025 financial results and highlighted progress; no headline surprises were reported in the summary notice. Full-year 2025 results
• Neutral Sentiment: Consensus brokerage coverage remains constructive (“Moderate Buy”), reflecting overall analyst support but not an immediate catalyst. Consensus recommendation coverage
• Neutral Sentiment: Reported short-interest entries show inconsistent/zero values (data artifact), so there’s no clear evidence of rising short pressure based on the published figures.
• Negative Sentiment: Despite the bullish signals above, AVBP is trading down on heavy volume — likely profit-taking, option-driven hedging flows, or broader market weakness outweighing analyst upgrades in the near term. Investors should watch intraday volume, near-term option activity, and any sector-wide moves for further direction.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.